Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS

• Status: Terminated
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Several investigations have suggested that polyunsaturated fatty acids may promote therapeutic effects in MS. This pilot study will determine whether omega-6 polyunsaturated fatty acids (PUFAs),in the form of linoleic acid,can reduce disease activity and prevent disability progression in patients with relapsing MS.This study will seek to measure disease activity as seen on MRI scans in addition to measuring relapse rates.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Rochester

Criteria

Inclusion Criteria:

1. Relapsing MS

2. treated with FDA-approved dosage of interferon-beta (Avonex,Betaseron,Rebif), glatiramer acetate for at least 6 months OR no immunotherapy for at least 3 months

3. at least one clinical exacerbation or at least one gadolinium enhancing lesion on brain MRI in the past 12 months

4. at least two gadolinium enhancing lesions on three brain MRIs obtained during the placebo run-in period

5. women of childbearing potential may participate provided that they are using adequate birth control methods for the duration of the study. Women of childbearing potential must have a negative pregnancy test at baseline and be non-lactating.

6. willing and able to provide informed consent

Exclusion Criteria:

1. corticosteroids within 1 month prior to screening

2. treatment with other immunotherapies (other than interferon-beta, glatiramer acetate or sporadic corticosteroids) within 3 months prior to screening

3. any significant medical condition or laboratory abnormality which may interfere with the subject's ability to participate in the study, including peptic ulcer disease, avascular necrosis and hepatic insufficiency

4. history of hypersensitivity or intolerability to vegetable oils or their constituents

5. unable to perform any of the required study procedures